MNKD241227P3000
- 0.00
- 0.000.00%
MannKind Newsroom
MannKind Shares Rise After Wells Fargo Begins Coverage
Leerink Partners Maintains MannKind(MNKD.US) With Buy Rating, Announces Target Price $9
RBC Capital Upgrades MannKind(MNKD.US) to Buy Rating, Raises Target Price to $10
Wells Fargo Initiates MannKind(MNKD.US) With Buy Rating, Announces Target Price $9
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target
MannKind (NASDAQ:MNKD) Pulls Back 3.8% This Week, but Still Delivers Shareholders Fantastic 36% CAGR Over 5 Years
MannKind Analyst Ratings
RBC Upgrades MannKind on Royalty Revenue, Orphan Lung Pipeline
Express News | MannKind Corp : RBC Raises to Outperform From Sector Perform; Raises Target Price to $10 From $7
MannKind Corporation Reduces Debt by $194 Million and Strengthens Cash Position to Over $180 Million
Express News | MannKind Corp: Debt Reduced by $194 Mln
Leerink Partners Keeps Their Buy Rating on MannKind (MNKD)
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MannKind Shares Are Falling Today: What's Going On?
MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint
Express News | MannKind Announced Six-month Results From Its Phase 3 Inhale-1 Study Of Afrezza (Insulin Human) Inhalation Powder In Children And Adolescents (Aged 4-17 Years). MannKind Expects To Submit A Request For Supplemental New Drug Application Meeting With...
Express News | MannKind Corp: Primary Endpoint Was Non-Inferior Change in Hba1C Levels After 26 Weeks
Express News | MannKind Corp: Expects to Ship Product for Cipla Ltd. by End of 2025
CDSCO Approves Afrezza (Insulin Human) Inhalation Powder in India